Jean-Charles Soria to B7-H1 Antigen
This is a "connection" page, showing publications Jean-Charles Soria has written about B7-H1 Antigen.
Connection Strength
2.417
-
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541.
Score: 0.508
-
JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. Cancer Discov. 2017 02; 7(2):128-130.
Score: 0.499
-
Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018 12; 15(12):748-762.
Score: 0.142
-
Bull Cancer. 2018 Dec; 105 Suppl 1:S59-S67.
Score: 0.142
-
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019 02 01; 25(3):946-956.
Score: 0.140
-
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018 09; 19(9):1180-1191.
Score: 0.139
-
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
Score: 0.138
-
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018 09; 101:160-164.
Score: 0.138
-
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
Score: 0.132
-
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Eur J Cancer. 2017 12; 87:65-74.
Score: 0.131
-
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
Score: 0.129
-
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Ann Pathol. 2016 Jan; 36(1):94-102.
Score: 0.116
-
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
Score: 0.032
-
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clin Cancer Res. 2016 Sep 01; 22(17):4309-21.
Score: 0.030